Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
11:30am, Wednesday, 08'th Jul 2020
Novocure announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua.
The 2 Little-Known Growth Stocks I Bought Last Week
10:00am, Wednesday, 08'th Jul 2020
Novocure is on a mission to give people with cancer a fighting chance. The company is commercializing a brand-new modality of cancer treatment, called tumor treating fields (TTFields). This idea sou
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
11:30am, Tuesday, 07'th Jul 2020
Novocure has enrolled the last patient in the HEPANOVA trial testing Tumor Treating Fields in combination with sorafenib in advanced liver cancer.
Novocure to Report Second Quarter 2020 Financial Results
11:30am, Wednesday, 01'st Jul 2020
Novocure will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open.
Has NovoCure Limited (NASDAQ:NVCR) Stock's Recent Performance Got Anything to Do With Its Financial Health?
04:02pm, Thursday, 18'th Jun 2020
NovoCure's (NASDAQ:NVCR) stock up by 5.6% over the past three months. As most would know, long-term fundamentals have...
Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR)
05:07am, Monday, 08'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR)
11:59am, Sunday, 07'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
11:30am, Tuesday, 02'nd Jun 2020
A new tool will enable patients to download their Optune usage data without the need for an in-person visit by a Novocure Device Support Specialist.
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
02:10pm, Wednesday, 13'th May 2020
Novocure and Zai Lab announced that China NMPA approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma.
Is NovoCure Limited (NASDAQ:NVCR) Potentially Undervalued?
02:21pm, Monday, 04'th May 2020
NovoCure Limited (NASDAQ:NVCR), which is in the medical equipment business, and is based in Jersey, received a lot of...
NovoCure Limited (NVCR) Q1 2020 Earnings Call Transcript
03:30pm, Saturday, 02'nd May 2020
On behalf of the entire NovoCure team, we would like to begin by wishing you well as we collectively face the challenges of the COVID-19 pandemic. Pritesh Shah, our Chief Commercial Officer; and Ely
Should You Use NovoCure’s (NASDAQ:NVCR) Statutory Earnings To Analyse It?
02:59pm, Friday, 01'st May 2020
Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Guggenheim likes Seattle Genetics in premarket analyst action
11:42am, Friday, 01'st May 2020
Axcella Health (NASDAQ:AXLA) initiated with Buy rating and $10 (115% upside) price target at BTIG Research.Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating and $9 (56% upside) price target
NovoCure (NVCR) Receives a Hold from Oppenheimer
10:17am, Friday, 01'st May 2020
Oppenheimer analyst Esther Rajavelu assigned a Hold rating to NovoCure (NVCR) today and set a price target of $78.00. The company's shares closed last
NovoCure (NVCR) Receives a Hold from Oppenheimer
10:17am, Friday, 01'st May 2020
Oppenheimer analyst
Esther Rajavelu
assigned a
Hold
rating to NovoCure (
NVCR
–
Research Report
) today and set a price target of
$78.00
. The company’s shares closed last Thursday at $65.80.
Acco
